Melanoma: The pipeline from start to finish.
By Aine Slowey, Lead Analyst
6 November 2014
I am the Lead Analyst for cardiovascular and metabolic diseases at Datamonitor Healthcare. I have a DPhil in Organic Che...
Read full bio
Malignant melanoma has a history of being difficult to treat due to the physiology of its tumors. However, the approvals of Yervoy and Zelboraf in 2011, together with more recent approvals, have revitalized development in the melanoma market. Future treatments will be reliant on new combination therapies in order to prevent the development of drug resistance, with ongoing trials evaluating combinations with therapies such as Yervoy and Keytruda.
Datamonitor Healthcare has reviewed the candidates in development for melanoma across the US, Japan, and five major EU markets, highlighting key trends, analyzing clinical trial design and innovative early-stage projects, and hypothesizing on how future treatments may emerge.
How will our melanoma pipeline report benefit you?
- Identify early-phase opportunities
Access our exclusive interactive early-phase forecast model as well as an in-depth analysis of key modes of action, enabling you to identify any investment opportunities within the pipeline.
- Unmet needs
Improve your chances of success in the melanoma market by recognizing the increased need for correct patient selection for clinical trials, in particular for patients segmented by BRAF mutation status.
- Future of treatment
Understand how and why new combination therapies will carve the way for future treatments in the melanoma market so that you’re able to enter the market successfully.
Key questions answered
- How will each pipeline therapy compare to the gold-standard therapies Yervoy and Zelboraf?
- What are the key factors for a good clinical trial design in melanoma?
- What key modes of action present in the early-phase pipeline have the potential to be the most commercially successful?
|Drug List:||Companies Mentioned:|
Posted in Oncology.